Literature DB >> 19255873

Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy.

M J van Breemen1, M de Fost, M Maas, M G Wiersma, C E M Hollak, L W Poll, S Vom Dahl, R G Boot, J M F G Aerts.   

Abstract

In tissue lesions of type I Gaucher patients, characteristic lipid-laden macrophages, 'Gaucher cells', are surrounded by inflammatory phagocytes. Gaucher cells secrete the elevated plasma chitotriosidase. The elevated plasma MIP-1beta in Gaucher patients stems from the phagocytes surrounding the Gaucher cells. Plasma chitotriosidase and MIP-1beta decrease upon successful enzyme replacement therapy (ERT) with mannose-terminated recombinant glucocerebrosidase (alglucerase). Previous histochemical analysis of Gaucher spleens revealed that Gaucher cells express little mannose receptor, in contrast to surrounding phagocytes. We therefore investigated the corrective effects of ERT on plasma MIP-1beta and chitotriosidase in more detail. We also compared effects of one year of treatment with a relatively low dose and a relatively high dose of ERT. A more rapid correction in plasma MIP-1beta, compared to chitotriosidase, was observed in most patients on low-dose ERT. Correction of plasma MIP-1beta and chitotriosidase levels was more pronounced in the higher-dosed patient group. Upon prolonged treatment, differences in the effects of enzyme dose were no longer significant. Normalization of plasma MIP-1beta and chitotriosidase levels was attained in the majority of patients. In conclusion, ERT with mannose-terminated gluocerebrosidase results in prominent corrections of plasma chitotriosidase, a marker of Gaucher cells, and in particular of plasma MIP-1beta, a marker of inflammatory phagocytes. The sharper response in plasma MIP-1beta to ERT is in line with the observation that especially phagocytes surrounding Gaucher cells express mannose-receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255873     DOI: 10.1007/s10545-009-1064-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  17 in total

1.  Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis.

Authors:  Maaike de Fost; Carla E M Hollak; Johanna E M Groener; Johannes M F G Aerts; Mario Maas; Ludger W Poll; Maaike G Wiersma; Dieter Häussinger; Sarah Brett; Nicole Brill; Stephan vom Dahl
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113

2.  Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease.

Authors:  C E Hollak; L Evers; J M Aerts; M H van Oers
Journal:  Blood Cells Mol Dis       Date:  1997-08       Impact factor: 3.039

3.  Glucocerebrosidase genotype of Gaucher patients in The Netherlands: limitations in prognostic value.

Authors:  R G Boot; C E Hollak; M Verhoek; P Sloof; B J Poorthuis; W J Kleijer; R A Wevers; M H van Oers; M M Mannens; J M Aerts; S van Weely
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

4.  Monitoring of Gaucher patients with a novel chitotriosidase assay.

Authors:  Aricha Schoonhoven; Bernard Rudensky; Debbie Elstein; Ari Zimran; Carla E M Hollak; Johanna E Groener; Johannes M F G Aerts
Journal:  Clin Chim Acta       Date:  2007-03-06       Impact factor: 3.786

5.  Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease.

Authors:  H Michelakakis; C Spanou; A Kondyli; E Dimitriou; S Van Weely; C E Hollak; M H Van Oers; J M Aerts
Journal:  Biochim Biophys Acta       Date:  1996-12-16

6.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

7.  Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease.

Authors:  Mariëlle J van Breemen; Maaike de Fost; Jane S A Voerman; Jon D Laman; Rolf G Boot; Mario Maas; Carla E M Hollak; Johannes M Aerts; Farhad Rezaee
Journal:  Biochim Biophys Acta       Date:  2007-04-14

8.  The human chitotriosidase gene. Nature of inherited enzyme deficiency.

Authors:  R G Boot; G H Renkema; M Verhoek; A Strijland; J Bliek; T M de Meulemeester; M M Mannens; J M Aerts
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

9.  Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts.

Authors:  S Van Weely; M B Van Leeuwen; I D Jansen; M A De Bruijn; E M Brouwer-Kelder; A W Schram; M C Sa Miranda; J A Barranger; E M Petersen; J Goldblatt
Journal:  Biochim Biophys Acta       Date:  1991-06-05

10.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more
  2 in total

1.  Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response.

Authors:  Nick Dekker; Laura van Dussen; Carla E M Hollak; Herman Overkleeft; Saskia Scheij; Karen Ghauharali; Mariëlle J van Breemen; Maria J Ferraz; Johanna E M Groener; Mario Maas; Frits A Wijburg; Dave Speijer; Anna Tylki-Szymanska; Pramod K Mistry; Rolf G Boot; Johannes M Aerts
Journal:  Blood       Date:  2011-08-25       Impact factor: 22.113

Review 2.  Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.

Authors:  Johannes M F G Aerts; Wouter W Kallemeijn; Wouter Wegdam; Maria Joao Ferraz; Marielle J van Breemen; Nick Dekker; Gertjan Kramer; Ben J Poorthuis; Johanna E M Groener; Josanne Cox-Brinkman; Saskia M Rombach; Carla E M Hollak; Gabor E Linthorst; Martin D Witte; Henrik Gold; Gijs A van der Marel; Herman S Overkleeft; Rolf G Boot
Journal:  J Inherit Metab Dis       Date:  2011-03-29       Impact factor: 4.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.